List of Personalized Medicine Companies in United Kingdom - 20

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company’s lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was founded in 2016 and is headquartered in London, the United Kingdom.

We turn ordinary scans into extraordinary insights because every patient deserves expert-level care, anywhere. Impactful. Scalable. Smart. Brainomix 360 enhances stroke imaging interpretation for neurologists, interventionalists, and radiologists while seamlessly fitting into existing radiology workflows. Delivering the right insights, to the right people, at the right time. Since our 2010 spin-out from the University of Oxford, we've developed award-winning, AI-powered imaging biomarkers and software solutions that empower physicians worldwide to make critical, life-saving decisions in stroke and lung care.

Carcinotech provides comprehensive solid tumour research services to therapeutic developers and healthcare professionals. At the heart of its offerings is the proprietary Carcino3D™ bioprinting platform, which creates assay-ready, 3D tumours from patient biopsies. Unlike conventional cancer models, Carcinotech’s bioprinted constructs incorporate multiple cell types—including immune cell populations—within a robust tissue matrix, offering a more biologically relevant and controlled model for early drug discovery, preclinical and co-clinical studies, and personalised treatment testing.

Starting with a vision to truly take paternity testing to the general public, Complement Genomics has been bringing forward new DNA testing services since 2000. Working in areas as diverse as clinical trials and non-human DNA testing, the highly trusted company has considerable expertise in pharmacogenetics. Complement Genomics also provides COVID-19 testing for private clients and businesses. Operating from the Durham Genome Centre, Complement Genomics has developed different brands according to the market segment: - dadcheck®gold - DNA testing services for professionals, including solicitors, barristers, local authorities and social services - dadcheck®silver - a full range of DNA testing services for the general public, including paternity and other human relationships, for the determination of parentage, for immigration DNA tests or for DNA tests which are suitable for other legal purposes - Chxout - services designed to serve the non-human DNA testing market – for citizen scientists and professionals alike. Bat Species Identification | Bird Sexing | Bird Species Identification | Bird Parentage | DNA Barcoding of animals, plants and fungi - Geneblitz - designed to serve the CRO and pharmaceutical sector with genotyping and phenotyping for clinical trials - That DNA Company - an online value brand providing DNA testing services, primarily paternity tests, for the general public

Enigma Diagnostics is a PCR-based testing out of the laboratory with a range of simple-to-use products.

Epoch's biorecycling platform unlocks circularity for the toughest-to-recycle materials. Our AI-designed enzymes enable infinite recycling for mixed plastics and textiles at low temperatures. We produce sustainable outputs for use in apparel, automotive, packaging and more.

Esox Biologics utilises their extensive knowledge of the aquatic microbiome to provide disease prevention solutions that help improve livestock health and welfare.

We are a Bioinformatics Provider with clients in the UK, Europe and America. With over 15 years of experience in supporting scientists, researchers and bioinformaticians in data analysis, we have an extensive experience in handling all types of datasets for drug discovery & development, diagnostics, agricultural research, veterinary medicine and applied research across all species. Our specialised team of bioinformaticians, statisticians and biologists are able to analyse and interpret any genomic, transcriptomic, proteomic & metabolomic data, independent of the platform used. We are very well appreciated among our clients for our proprietary computer solutions that allow parallelisation of large datasets analysis that saves processing time and avoids the complications that arise when analysing data in batches. Results of the analysis are always presented in a secure web report that is complete with all references and results. Types of services offered by FIOS: ● Technology/Platform Selection ● Study Design & Biostatistics ● Data QC and Pre-processing ● Biomarker Identification & Validation ● Genomic Signature Development ● Data Visualisation ● Preclinical Safety & Toxicology Investigations ● Clinical Trial Analysis ● Drug Repurposing For more info, get in touch: https://www.fiosgenomics.com/contact-us/ Twitter: @fiosgenomics Facebook: https://www.facebook.com/fiosgenomics/ Office Phone Number: +44 (0)131 322 3770 Office Address: Fios Genomics Ltd, BioCube 1, 13 Little France Road, Edinburgh BioQuarter, Edinburgh, EH16 4UX

genedrive plc is a molecular diagnostics company developing and commercialising a low-cost, rapid, versatile, simple to use and robust point of need molecular platform for use in patient stratification (genotyping). We are passionate about the opportunity to build a sustainable business around molecular diagnostics and to play an important role in the diagnostic and treatment challenges presented by global health issues. The company launched the Genedrive MT-RNR1 ID Kit, a pharmacogenetic test to prevent antibiotic induced deafness in infants, which was co-developed with the partners in the UK's National Health Service and is now used for routine clinical use.

We are a molecular diagnostics company working predominantly in the fields of infectious disease, cancer diagnostics and personalised medicine. Our ethos is to offer robust easy-to-use, sensitive, and affordable molecular diagnostics technologies and products to researchers, clinicians and drug companies to enable accurate diagnosis and the delivery of safe and effective medicines. Our patented technologies allow for simultaneous detection of multiple targets in one reaction. If you have a project or collaboration in mind, we'd love to hear from you! Do you have a requirement for detecting multiple targets? Are you working with bacteria, viruses or fungus? We can help you achieve what you need with our dedicated team of experts. Drop us a line here or email us at info@genefirst.com

GENinCode specializes in risk assessment and prediction of cardiovascular disease , thrombosis and familial hypercholesterolemia . Cardiovascular disease (CVD) is a broad disease classification including coronary artery disease such as angina and myocardial infarction often referred to as heart attack. CVD also includes stroke, heart failure, hypertension and other vascular heart diseases and is the leading cause of death and disability worldwide accounting for 1 in every 4 deaths in the United States. GENinCode provides advanced genomic technology, products and recommendations fully validated by our scientific and clinical team. Our goal is to provide doctors and health care practitioners with advanced health information that combines both traditional clinical measures with a patient's genetic information to provide a comprehensive risk assessment and clinical recommendation to help decision-making. Our technology helps select the optimal treatment pathway and informs and educates patients to become more aware of their cardiovascular risk helping patient adherence and empowerment to better manage their health. GENinCode technology and advanced genomic products provide information that helps patients and healthcare practitioners to assess and predict the onset of cardiovascular disease, thrombosis, and the diagnosis of Familial Hypercholesterolemia. Our online reporting system SITAB® helps inform doctors of their patients' health risk enabling patient behavioral and lifestyle changes alongside delivering the most effective therapies and treatment pathways.

GENinCode specializes in risk assessment and prediction of cardiovascular disease , thrombosis and familial hypercholesterolemia . Cardiovascular disease (CVD) is a broad disease classification including coronary artery disease such as angina and myocardial infarction often referred to as heart attack. CVD also includes stroke, heart failure, hypertension and other vascular heart diseases and is the leading cause of death and disability worldwide accounting for 1 in every 4 deaths in the United States. GENinCode provides advanced genomic technology, products and recommendations fully validated by our scientific and clinical team. Our goal is to provide doctors and health care practitioners with advanced health information that combines both traditional clinical measures with a patient’s genetic information to provide a comprehensive risk assessment and clinical recommendation to help decision-making. Our technology helps select the optimal treatment pathway and informs and educates patients to become more aware of their cardiovascular risk helping patient adherence and empowerment to better manage their health. GENinCode technology and advanced genomic products provide information that helps patients and healthcare practitioners to assess and predict the onset of cardiovascular disease, thrombosis, and the diagnosis of Familial Hypercholesterolemia. Our online reporting system SITAB® helps inform doctors of their patients’ health risk enabling patient behavioral and lifestyle changes alongside delivering the most effective therapies and treatment pathways.

DNA is the blueprint to what makes you who you are. It is the most valuable piece of personal information an individual will ever own. It is an appreciating asset that will continue to increase in value as genetic research continues to unlock mysteries in DNA over time. However, as soon as individuals send their saliva to a sequencing facility and their DNA is read, they relinquish all control over their data. Organisations that hold this data currently do not have the technology to safeguard it from data hacks/breaches and many legally share DNA data in plain text to third parties in multi-million dollar deals. This means that individuals not only are excluded from taking part in any value their DNA may hold but lose ownership and privacy of highly sensitive DNA data. We at Genomes.io believe individuals should be able to own, control access to and benefit from their most sensitive and valuable personal asset, their DNA. We are building a secure DNA sequencing, storage and sharing technology using state-of-the-art encryption and blockchain technologies to provide users with control over their whole genome sequence. This allows users to control access to segments of their genome in a repeat consent model to trusted professionals and accredited researchers in a secure, private and anonymous manner. Our platform acts as genomic data aggregator that provides research organisations with a more efficient genomic data acquisition model. However, we do so in a more equitable model in which individuals own, control and get paid for the data they wish to share. We aim to securely sequence and store 1 billion individual’s genomes in our DNA data bank and become the world’s largest, most secure and trusted genomic and health data marketplace to power the personalised medicine revolution. Genomes.io - Invest in Future You.

We are a pioneering healthcare company that aims to transform health through the power of genomics. The company was formed in 2014 by four world-leading statistical and human geneticists at the University of Oxford, including Professor Sir Peter Donnelly and Professor Gil McVean. We use large-scale genetic information to realise preventative medicine and improve drug discovery. We're a world-leader in genomic prevention: a paradigm-changing approach to sustainable healthcare which for the first time allows reliable, personalized estimates of risk for all the common diseases and cancers, well ahead of disease manifestation, allowing accurate and early interventions and tailored screening. Our proprietary algorithms and databases offer something no competitor can: the ability to accurately link minute variation across the entire genome to changes in thousands of biological measurements and disease outcomes, to generate population-level insights for healthcare systems, individual-level insights for clinicians about the risk of common diseases, and new understanding of disease processes. In August 2018, we announced a multi-year collaboration with Vertex to use human genetics and data science to advance discovery of precision medicines. We also has several pilot programmes in development within UK and US healthcare systems. Our team is a multi-disciplinary group focused on finding powerful and creative solutions for bringing subject-leading science to as wide an audience as possible, and, in doing so, offer the chance of transforming lives around the world. The workforce is highly qualified and consists of over 90 people, including genomic scientists, computational biologists, statisticians, software engineers, product developers, data scientists and commercial strategists. We are headquartered in Oxford, with offices in Cambridge (UK) and Boston (US).

Locate Bio bring together Programmed Drug Release and Instructive Tissue Scaffolds to develop the next generation of products with significant disruptive potential for musculoskeletal conditions.

NunaBio is a privately-owned specialist DNA synthesis and development company. We are engaged in CRO (Contract Research Organizations) and CDMO (Contract Development and Manufacturing Organisation) activities. The company has built a solid reputation for its R&D flexibility and innovative approach to complex and challenging projects. NunaBio's core expertise is research and development into cell-free DNA synthesis, process optimisation, route design, scale-up and small-scale manufacture for clinical studies.

Owlstone Medical is developing a breathalyzer for disease. With a goal of finding ways to improve non-invasive diagnostics for respiratory diseases, liver diseases, cancer, digestive health, and other conditions. Our mission is to save 100,000 lives and $1.5B in healthcare costs by advancing early detection and precision medicine. Breath Biopsy® aims to develop a new diagnostic modality making it possible to discover novel non-invasive biomarkers in breath using a platform with the potential to transition to point-of-care. The award-winning ReCIVA® Breath Sampler ensures the reliable collection of breath samples. The volatile organic compounds (VOCs) present in breath are analyzed using state-of-the-art chemical analysis technologies. Our aim is to develop tools, potentially based on our proven microchip chemical sensor technology (FAIMS), to detect validated biomarkers of disease. The Breath Biopsy platform provides biomarker discovery and validation capabilities to support the development of applications in precision medicine for a wide range of other medical conditions. Highly sensitive and selective, our platform allows for early diagnosis when treatments are more effective and more lives can be saved. Owlstone Medical is involved in studies related to major and rapidly growing health concerns including lung cancer, asthma and liver disease. We are also participants in extensive partnerships focusing on multiple cancer types, pulmonary hypertension, mesothelioma, workplace exposures and much more. Our Breath Biopsy Products and Services are available to academic, clinical, and pharma research partners who want to develop breath-based diagnostics for their own applications. Our products and services are for research use only. Not for use in diagnostic procedures.

Perspectum's imaging solutions are safe, fast, and can offer more comprehensive diagnostics. We help doctors understand complex data and help deliver precision care to more patients. We believe the voice of the patient matters and that each case is unique. Our goal is to enable health care providers to tailor precision medicine to the needs of the individual.

Physiomics specialises in integrating Modelling & Simulation, Biostatistics, Data Science, and Bioinformatics with disease biology expertise to help biotech and pharma companies streamline drug development. Our goal is to extract actionable insights from all relevant data to de-risk critical decisions across discovery, preclinical, and clinical stages. This includes the optimal design of preclinical and clinical studies to give your drug the best chance of success. We leverage cutting-edge computational tools, custom-built models, and our proprietary Virtual Tumour technology to provide tailored solutions that accelerate development and optimise outcomes for our clients. With a track record of supporting over 100 commercial projects and modelling more than 125 targets and drugs, Physiomics has become a trusted partner to industry leaders such as Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics, and CRUK.

Treos Bio is a clinical stage company introducing a disruptive computational technology to change the paradigm of cancer immunotherapy development by resolving the dual challenges of patient and tumor heterogeneity. We use proprietary therapeutic peptides, produced through commercially scalable processes without need for tumor biopsy, to stimulate clinically effective cancer-specific immune responses in patients predicted by our diagnostic tests to respond.